TEVA and AMGN Related Headlines
Go Back- FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'
- Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
- Bernstein on IRA pricing: $245 really is the floor
- White House: Trump took action on pharma Thursday, sent letters to CEOs
